Stocks Health care AUPH
NASDAQ · Health careAurinia Pharmaceuticals Inc. (AUPH)
Aurinia Pharmaceuticals Inc. brought in $321.7M of revenue over the twelve months to September 30, 2026, up 21.0% from a year earlier. Net income was $314.3M, a net margin of 97.7%. At September 30, 2026 it held $45.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 30, 2026.
Key facts about Aurinia Pharmaceuticals Inc.
- Net worth
- Aurinia Pharmaceuticals Inc. has a market value (market cap) of $2.2B at the latest share price, and shareholders' equity of $657.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- Over the 12 months to September 30, 2026: revenue $321.7M, net income $314.3M.
- Cash flow
- In fiscal 2025 operations brought in $135.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 30, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Aurinia Pharmaceuticals Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Aurinia Pharmaceuticals Inc. does
Aurinia Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AUPH.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $283.1M | $287.2M | $2.07 | n/a |
| 2024 | $235.1M | $5.8M | $0.04 | n/a |
| 2023 | $175.5M | -$78M | -$0.54 | n/a |
| 2022 | $134M | -$108.2M | -$0.76 | n/a |
| 2021 | $45.6M | -$181M | -$1.40 | n/a |
| 2020 | $50.1M | -$102.7M | -$0.87 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where AUPH ranks in Health care
Latest SEC filings
What Aurinia Pharmaceuticals Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 30, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 14% to $83.7M versus the same quarter last year; diluted EPS $0.23 versus $0.23.
- October 30, 2026
- August 26, 2026Activist stake changed SCHEDULE 13D/A
- August 19, 2026Other event 8-K
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 19% to $83.2M versus the same quarter last year; diluted EPS $0.28 versus $0.16.
- August 6, 2026
- June 4, 2026Activist stake changed SCHEDULE 13D/A
- June 4, 2026
- May 11, 2026
- May 11, 2026Tender offer (amended) SC TO-T/A
Insider trades
What the people running Aurinia Pharmaceuticals Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $546.4K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 10, 2026 | Robertson Stephen P.Chief Legal Officer | Sold | 11,939 | $190.4K |
| August 21, 2026 | Robertson Stephen P.Chief Legal Officer | Sold | 20,975 | $355.9K |
| June 2, 2026 | Tang KevinChief Executive Officer, Director, 10% owner | Boughtindirect | 206,005 | $3.1M |
| June 1, 2026 | Tang KevinChief Executive Officer, Director, 10% owner | Boughtindirect | 343,521 | $5.2M |
| June 1, 2026 | Tang KevinChief Executive Officer, Director, 10% owner | Boughtindirect | 99 | $1.5K |
| May 29, 2026 | Tang KevinChief Executive Officer, Director, 10% owner | Boughtindirect | 2,299 | $35.3K |
| May 29, 2026 | Tang KevinChief Executive Officer, Director, 10% owner | Boughtindirect | 262,682 | $4M |
| May 18, 2026 | Hearne Michael SChief Financial Officer | Received as pay | 116,144 | - |
Who owns AUPH
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Tang Capital Management, LLC13D, may seek influence with 5 related filers | 10% | June 4, 2026 |
| (voluntary) Chin Kyu Huh13D, may seek influence with 5 related filers | 5.2% | March 20, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 281 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Tang Capital Management LLC | 13,044,106 | +814,606 |
| BlackRock, Inc. | 8,193,085 | +347,564 |
| Goldman Sachs Group Inc | 5,619,401 | +4,185,893 |
| NEA Management Company, LLC | 3,969,834 | 0 |
| Two Sigma Investments, LP | 3,467,514 | +38,809 |
| Arrowstreet Capital, Limited Partnership | 3,264,062 | -20,306 |
| State Street Corp | 2,589,615 | +62,516 |
| Morgan Stanley | 2,308,244 | +75,696 |
| Marshall Wace, Llp | 2,044,007 | +169,410 |
| Geode Capital Management, LLC | 1,701,152 | +165,143 |
| Renaissance Technologies LLC | 1,548,035 | -115,800 |
| D. E. Shaw & Co., Inc. | 1,408,456 | -164,527 |
| Vanguard Portfolio Management LLC | 1,359,028 | +102,667 |
| Jacobs Levy Equity Management, Inc | 1,231,516 | +134,327 |
| Jupiter Asset Management Ltd | 1,094,475 | +291,056 |
| Nomura Holdings Inc | 978,602 | +9,692 |
| Aqr Capital Management LLC | 948,751 | -59 |
| Northern Trust Corp | 863,567 | +39,462 |
| Nuveen, LLC | 812,915 | +159,491 |
| Jupiter Topco LLC | 602,195 | new |
Insiders
10 insiders reported holding 17,154,157 shares in total, about $279.4M at the last price.
| Holder | Shares |
|---|---|
| Tang KevinChief Executive Officer, Director, 10% owner | 13,044,10613,044,106 held indirectly |
| Greenleaf PeterChief Executive Officer, Director | 1,840,379 |
| Donley Matthew MaxwellChief Operating Officer | 680,299 |
| Robertson Stephen P.Chief Legal Officer | 588,848 |
| Miller Joseph MChief Financial Officer | 576,421 |
| Keenan GregSVP, Chief Medical Officer | 154,449 |
| Hearne Michael SChief Financial Officer | 116,144 |
| Cole RyanChief Operating Officer | 116,144 |
| Bailey Jeffrey AllenDirector | 22,775 |
| Johnson Craig ADirector | 14,592 |
Questions about AUPH
What does Aurinia Pharmaceuticals Inc. do?
Aurinia Pharmaceuticals Inc. is a company in the Health care sector, listed on NASDAQ as AUPH. Its shares trade on NASDAQ under the ticker AUPH.
What is Aurinia Pharmaceuticals Inc.'s net worth?
Aurinia Pharmaceuticals Inc. has a market value (market cap) of $2.2B at the latest share price, and shareholders' equity of $657.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Aurinia Pharmaceuticals Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $314.3M on revenue of $321.7M, a net margin of 97.7%.
How much revenue does Aurinia Pharmaceuticals Inc. make?
Over the twelve months to September 30, 2026 Aurinia Pharmaceuticals Inc. reported revenue of $321.7M. That is 21.0% more than a year earlier.
When did Aurinia Pharmaceuticals Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 30, 2026. It covers the period to September 30, 2026.
When is Aurinia Pharmaceuticals Inc.'s next earnings report?
Aurinia Pharmaceuticals Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare AUPH with
Follow AUPH
Get an email when Aurinia Pharmaceuticals Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Aurinia Pharmaceuticals Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.